Perioperative Durvalumab Plus Neoadjuvant Chemotherapy Improves EFS and OS in Cisplatin-Eligible Patients with Muscle Invasive Bladder Cancer By Ogkologos - November 18, 2024 753 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NIAGARA study Source RELATED ARTICLESMORE FROM AUTHOR In Memory of Hernán Cortés-Funes: Former ESMO President and Pioneer in Medical Oncology Immune Pathways Help Identify Patients with Cancer and HIV Most Likely to Experience Reservoir Decay with Anti-PD1 Therapy Shaping Future Oncology Leaders: ESMO Broadens Its Career Development Opportunities MOST POPULAR Snowboarder Kimmy Fasani Diagnosed with Breast Cancer Nine Months After Son’s... December 11, 2021 Should People With Cancer Be Tested for Hepatitis B? July 27, 2020 Mom Unknowingly Has Cancer For 3 Years After Doctor Keeps Telling... March 21, 2019 ESMO World Congress on Gastrointestinal Cancer 2021, 30 June – 3... June 23, 2021 Load more HOT NEWS Remembering With Gratitude TIL Densities Association with Disease-Free Survival Differs by Primary Tumour Sidedness... What Is a Living Will and Why Should You Create One... Utility of a Methylation-Based Multicancer Early Detection Test in Identifying Whom...
